StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report report published on Thursday morning. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 price target on shares of Arcadia Biosciences in a research report on Wednesday, August 21st.

Arcadia Biosciences Trading Down 0.7 %

Shares of Arcadia Biosciences stock opened at $4.05 on Thursday. The stock’s fifty day moving average price is $3.24 and its 200-day moving average price is $2.96. The firm has a market cap of $5.52 million, a P/E ratio of -0.81 and a beta of 1.27. Arcadia Biosciences has a 12 month low of $1.85 and a 12 month high of $5.34.

Arcadia Biosciences (NASDAQ:RKDA) last posted its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 EPS for the quarter, missing analysts’ consensus estimates of $1.27 by ($0.49). Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. The business had revenue of $1.31 million for the quarter, compared to analysts’ expectations of $0.95 million. During the same period last year, the business posted ($2.64) EPS. Analysts forecast that Arcadia Biosciences will post -1.7 earnings per share for the current year.

About Arcadia Biosciences

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.